|Impact of Molecular Surface Charge on Electrical Impedance Spectroscopy Biosensing|
Y. Ram, T. Yoetz-Kopelman, A. Freeman and Y. Shacham-Diamand
Molecular surface charge was found to be the dominant parameter when monitoring protein binding events by Electrical Impedance Spectroscopy with a charged redox couple. A biosensing device was fabricated, and a physical model was derived to explain the results.
|Droplet-on-Demand Platform for Biochemical Screening & Drug Discovery|
L.D. van Vliet1*, F. Gielen1, A. Sinha2, B.T. Koprowski3, J.B. Edel4, X.Niu5, A.J. deMello3, F. Hollfelder1, & J. Motschman2
To demonstrate droplet on demand applications towards study of biological entities encapsulated in nanoliter droplets. Interfacing a droplet on demand platform with microfluidic chips allows for merging and dilution of droplets. This feature is applied to encapsulate yeast cells (S. cerevisiae) and multicellular organisms (C. elegans).
|Investigating the Effects of Commercial Antimicrobial Agents on Human Corneal Epithelial Cell Membranes|
Ian J. Horner, Jerod J. Hurst, Nadine D. Kraut, Alyssa A. Rook, Crystal M. Collado, G Ekin-Atilla Gokcumen, and Frank V. Bright
Several commercial multi-purpose solutions (MPS) products contain polyhexamethylene biguanide (PHMB) and/or polyquaternium-1 (PQ-1) as antimicrobial agents. In this poster we report the effects of PHMB and PQ-1 on small unilamellar vesicles (SUV) that we have designed to mimic the average human corneal epithelial cell membrane.
|Direct Targets Identification of a Bioactive Compound|
Sylvain Blanc, Paul Bradley, Marie-Edith Gourdel, Michael Cholay, Gisèle Guimèse, Mike Mckenzie, George Nasi, Jean-Christophe and Barbara Ruggiero
Identifying protein partners of a small bioactive molecule is of great
interest in many aspects of life sciences and specifically in the drug
discovery and development process cycle. It is a support to (i) decipher
the mechanism of action after for example a “High Content” screening,
(ii) study “off-target” effects, (iii) adjust therapeutic indications and
clinical regimens of a drug and (iv) consider drug repositioning.
|3D-Tissue/ Whole-blood Co-culture Models Combined with Multi-Analyte Profile (MAP) Analyses for In-vivo-like Immunopharmacology|
Stein GM, Joos T, Schmolz M
Human Organotypic Test (HOT) Systems aim at in-vivo like substance characterisation of all preparations meant to act on the human immune system.
|A multiplexed amplicon sequencing technology for FFPE and circulating, cell-free DNA|
Laurie Kurihara, Catherine Couture, Julie Laliberte, Sukhinder Sandhu, Jonathan Irish, Tim Harkins and Vladimir Makarov
A novel amplicon approach allowing for hundreds of amplicons to be multiplexed in a single tube with a two workflow from sample to sequencer.
|Phenotypic Screening Applied to the Anti-biofilm Drug Discovery: Identification of Anti-biofilm Flavonoids from a Chemical Library|
Suvi Manner1*, Malena Skogman2, Pia Vuorela2, Adyary Fallarero2
This work represents a systematic exploration of a flavonoids collection for the inhibitory activity against Staphylococcus aureus biofilms and offers an improved methodological workflow for anti-biofilm screens of chemical libraries taking into account the connections between anti-biofilm and antibacterial properties.
|EU-OPENSCREEN - The European Research Infrastructure of Open Screening Platforms for Chemical Biology|
EU-OPENSCREEN (www.eu-openscreen.eu) is the largest emerging academic chemical biology research infrastructure initiative in Europe with the aim to collaboratively develop novel research tool compounds with external scientists. As a joint effort of national networks in 16 European countries, EU-OPENSCREEN offers access to high-throughput screening platforms, chemistry services, an open-access database, a large compound collection and an open-access database.
|Fighting Blindness with 3D-NET "Drug Discovery & Development of Novel Eye Therapeutics"|
Pilar Ventosa-Andrés, Nils Ohnesorge, Yolanda Fernández, Yolanda Alvarez and Breandán Kennedy
3D-NET, “Drug Discovery & Development of Novel Eye Therapeutics”, is a new European research consortium of industry and academic partners focusing efforts to enhance the discovery and development of drugs targeting ocular pathologies that lead to blindness.